Australia's PYC Therapeutics soars on safety approval for its kidney disease drug trial

PYC Therapeutics

07/07/2025 06:06

** Shares of Australia's PYC Therapeutics Ltd PYC.AX rise 11.3% to A$1.425, their highest level since late December 2024

** Stock set for best day since September 26, 2024, if trend holds

** Biotechnology firm gets approval from the safety review committee to advance the clinical study of drug candidate PYC-003

** PYC-003 is meant to address polycystic kidney disease

** YTD, stock up 8.5%, including the session's gains

(Reporting by Shruti Agarwal in Bengaluru)

((Shruti.AgarwalRoshan.Thomas@thomsonreuters.com))